Fragile X syndrome (FXS) is a rare genetic disorder caused due to the mutations in the Fragile X mental retardation 1 (FMR1) gene. Also known as Martin-Bell syndrome, the disease occurs due to the absence of a protein – Fragile X mental retardation protein (FMRP) – required for normal development of the body.
DelveInsight’s “Fragile X Syndrome Market Insights and Forecast Report” delivers an in-depth understanding of the Fragile X Syndrome (FXS), historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan, for the study period 2017-30.
The Fragile X syndrome market report proffers a comprehensive view of epidemiological analysis – historical and forecasted, diagnosis approaches, present treatment regimen, upcoming novel therapies, and unmet needs along with drivers and barriers present in the Fragile X syndrome market.
Fragile X Syndrome Market: Disease Understanding and Therapies available
The DelveInsight Fragile X Syndrome (FXS) market report gives a detailed understanding of the Fragile X Syndrome (FXS) by including particulars such as disease description, symptoms, causes, pathophysiology, diagnosis and treatment.
As per the Orphanet registry, worldwide Fragile X syndrome prevalence is estimated at approximately 1/4000-1/5000.
The FXS market report offers insights into historical and 11-year forecasted Fragile X Syndrome (FXS) patient pool and forecasted trend for 7MM countries. It helps to identify the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
At present, Fragile X syndrome has no cure. However, to ease the symptoms, there present special education, speech, occupational, sensory integration training, and behavior modification programs.
The report covers a detailed view of the conventional as well as present treatment approaches for Fragile X syndrome, providing treatment algorithms and guidelines in the United States, EU5, and Japan.
Fragile X Syndrome Market: Marketed, and Upcoming Drugs
Pharma players and biotech companies including Zynerba Pharmaceuticals, Seaside Therapeutics, Ovid Therapeutics, Neuren Pharmaceuticals, Tetra Discovery Partners, Neurotrope Bioscience and many more, are advancing the Fragile X syndrome market forward.
The Fragile X syndrome market report covers detailed picture of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. The report helps in providing a better understanding of clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Fragile X Syndrome Market landscape
The Fragile X Syndrome market outlook proffers a detailed comprehension of the historic, current, and forecasted Fragile X Syndrome (FXS) market trends by scrutinizing the impact of current therapies on the Fragile X Syndrome market, unmet needs, drivers and barriers and demand of better expertise.
The Fragile X syndrome market report covers each marketed drug and late-stage pipeline therapy with their cost, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, expected launch year, competitive analysis, brand value, their impact on the market and view of the key opinion leaders.
According to DelveInsight, Fragile X Syndrome (FXS) market in 7MM is expected to change in the study period 2017-2030.
Fragile X Syndrome Report Highlights
- Dynamic Fragile X Syndrome market trends
- Healthcare spending fuelling Fragile X Syndrome Market
- Collaborations, mergers, and acquisitions in FXS Market
- Challenges poised and opportunities present influencing Fragile X Syndrome Market
- R&D driving FXS Market
- Novel therapies and drugs in Fragile X syndrome pipeline
- Major players involved impacting Fragile X Syndrome (FXS) market
- In-depth analysis of the pipeline products (Phase III and Phase II), comparative analysis with detailed clinical profiles, key cross-competition, launch date along with product development activities
Table of Contents
1. Key Insights
2. Executive Summary of Fragile X Syndrome (FXS)
3. Competitive Intelligence Analysis for Fragile X Syndrome (FXS)
4. Fragile X Syndrome (FXS): Market Overview at a Glance
5. Fragile X Syndrome (FXS): Disease Background and Overview
6. Patient Journey
7. Fragile X Syndrome (FXS) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Fragile X Syndrome (FXS) Treatment
11. Marketed Products
12. Emerging Therapies
13. Fragile X Syndrome (FXS): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Fragile X Syndrome (FXS)
17. KOL Views
18. Market Drivers
19. Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; will be provided in the final report
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.
Browse through our vast repository from here.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States